Stocks of Immunogen, Inc. (NASDAQ:IMGN) traded higher last session on Wall Street, down -0.34% to $29.22.
According to the data, Immunogen, Inc. (NASDAQ:IMGN) has 14 analysts covering its stock. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $31.26 and a low of $19.00, we find $31.00. Given the previous closing price of $29.32, this indicates a potential upside of 5.73 percent. IMGN stock price is now 86.27% away from the 50-day moving average and 125.18% away from the 200-day moving average. The market capitalization of the company currently stands at $7.78B.
A total of 11 analysts have issued a hold rating and 3 have given it a buy rating. Brokers who have rated the stock have averaged $29.48 as their price target over the next twelve months.
With the price target enhanced from $25 to $31, Guggenheim Downgraded its rating from Buy to Neutral for Immunogen, Inc. (NASDAQ: IMGN).
In other news, Wingrove Theresa, SVP OF REGULATORY AFFAIRS sold 164,424 shares of the company’s stock on Nov 30. The stock was sold for $4,760,075 at an average price of $28.95. Upon completion of the transaction, the SVP OF REGULATORY AFFAIRS now directly owns 2,811 shares in the company, valued at $82137.42. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 29, SVP OF REGULATORY AFFAIRS Wingrove Theresa sold 6,792 shares of the business’s stock. A total of $113,155 was realized by selling the stock at an average price of $16.66. This leaves the insider owning 2,811 shares of the company worth $82137.42. Insiders disposed of 4,269,035 shares of company stock worth roughly $124.74 million over the past 1 year. A total of 2.57% of the company’s stock is owned by insiders.
Monday’s opening bell rang with an opening price of $29.10 for Immunogen, Inc. (NASDAQ: IMGN). During the past 12 months, Immunogen, Inc. has had a low of $3.61 and a high of $29.44. As of last week, the company has a debt-to-equity ratio of 0.20, a current ratio of 5.70, and a quick ratio of 5.65. The fifty day moving average price for IMGN is $15.69 and a two-hundred day moving average price translates $12.98 for the stock.
The latest earnings results from Immunogen, Inc. (NASDAQ: IMGN) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at $0.1, beating analysts’ expectations of $0.04 by 0.06. This compares to -$0.31 EPS in the same period last year. The net profit margin was -25.56% and return on equity was -19.88% for IMGN. The company reported revenue of $113.42 million for the quarter, compared to $15.38 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 637.72 percent. For the current quarter, analysts expect IMGN to generate $129.47M in revenue.
Immunogen, Inc.(IMGN) Company Profile
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
